Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6P5S7
UPID:
RNK_HUMAN
Alternative names:
V-type proton ATPase subunit f
Alternative UPACC:
Q6P5S7; G3V1Z9; Q502Z2
Background:
Ribonuclease kappa, also known as V-type proton ATPase subunit f, plays a crucial role in cellular processes by preferentially cleaving ApU and ApG phosphodiester bonds, and to a lesser extent, UpU bonds. It is instrumental in regulating the activity of vacuolar (H+)-ATPase, essential for acidifying intracellular compartments, and is pivotal in the early stages of receptor-mediated endocytosis.
Therapeutic significance:
Understanding the role of Ribonuclease kappa could open doors to potential therapeutic strategies.